Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Colby who wrote (10997)	7/9/1998 5:48:00 PM
From: david	Read Replies (2) \| Respond to of 23519

it is rare that a company mentions clearly the possible buyout. this suggests Vivus does not have confidence in itself. I think Vivus has already done and said whatever they could for the company. they are desperate right now. i am quite doubting the motivation of PW's upgrade now. d.

To: Colby who wrote (10997)	7/10/1998 7:55:00 AM
From: DaiS	Read Replies (1) \| Respond to of 23519

Possibly another for Alien's collection. If Leland truly said that Alibra is 26% more effective he blundered unless there is new data I have not seen. The Costabile study at the AUA meeting had 376 men 187 successful with muse a further 89 successful with alibra Success rates muse 187/376 = 47% Alibra (or muse) 276/376 = 70% Therefore, Alibra can truly be said to be said to be -(1- 70/47) * 100 = 48% more effective than muse. If Leland simply took a difference ie 70%-47% = 23%, he could say '47% men had success with muse and a further 23% had success with Alibra.' Appears he chose the worst possible spin. Anyway on this AUA evidence he could truthfully say, Independent evidence suggests that ALIBRA is almost 50% more effective than MUSE